Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bomedemstat + Ruxolitinib in Myelofibrosis
NCT05569538Phase 2Recruiting
- Sponsor
- The University of Hong Kong
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bomedemstat in myelofibrosis (MF) (2 cohorts), sponsored by The University of Hong Kong. Primary endpoint: Adverse events at 24 months. Started Dec 2022; status: recruiting.
02
Drugs
bomedemstat
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05569538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05569538.